Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).

Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec; 295(3):912-26.

View in: PubMed

subject areas

Animals
Anti-Asthmatic Agents
Arachidonate 5-Lipoxygenase
Arachidonic Acid
Calcimycin
Enzyme Inhibitors
Eosinophils
Female
Janus Kinase 3
Leukotriene C4
Male
Mast Cells
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, SCID
Protein-Tyrosine Kinases
Quinazolines
Receptors, IgE

authors with profiles

Christopher Navara

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support